Vaginal microbicides
This article was originally published in The Tan Sheet
Executive Summary
Researchers at the University of California-San Francisco announce they are seeking women aged 18 to 24 to participate in the first U.S. safety study of a vaginal microbicide to prevent herpes and HIV infection. VivaGel (3% w/w SPL7013) is designed to prevent herpes and HIV infection through the use of a dendrimer molecule. Herpes and HIV molecules are "caught" in the dendrimer branches and prevented from entering and infecting human cells, lead researcher Anna-Barbara Moscicki, MD, says Nov. 29. In related news, the Canadian government announces Dec. 1 a $13.2 mil. donation to the International Partnership for Microbicides to support product development and clinical trials of microbicides for women in developing countries. In August, the Global HIV Prevention Working Group issued a report encouraging increased manufacturing of microbicides to meet public need (1"The Tan Sheet" Aug. 21, 2006, p.7)...
You may also be interested in...
Microbicide Manufacturing Capacity Ramp-Up Urged In HIV Report
Development of sufficient manufacturing capacities for microbicides will likely need to begin years in advance of regulatory approval in order to meet public health needs, an HIV prevention working group says
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.